Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Part D Cost Trends: A Good News/Bad News Story For Biopharma

Executive Summary

Despite headlines about soaring drug costs, Medicare Part D beneficiaries are not seeing much if any increase in their out-of-pocket spending. But that doesn’t necessarily mean that costs of the program are stable – which could open up a new area for policy activity in 2017 and beyond.

Advertisement

Related Content

Medicare Part D Catastrophic Spending Surge Needs Solutions, OIG Says
Paying For Cures Requires Bigger Budgets, Not Lower Drug Prices – Execs
Part D Reform Proposals From MedPAC May Find Traction After Election
Thinking Outside The Box On Rx Pricing: From Vaccines To Part D Bundling
Drug-Pricing Help Wanted: Wyden, Grassley Seek Public Input On Policy Ideas

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS118896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel